Andrew Lloyd Lundquist, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Glomerulonephritis, IGA | 1 | 2020 | 66 | 0.700 |
Why?
|
| Nephrology | 1 | 2020 | 263 | 0.570 |
Why?
|
| Hyperphosphatemia | 1 | 2016 | 40 | 0.540 |
Why?
|
| Hyperparathyroidism, Secondary | 1 | 2016 | 126 | 0.510 |
Why?
|
| Potassium Channels, Voltage-Gated | 2 | 2005 | 142 | 0.490 |
Why?
|
| Outpatients | 1 | 2020 | 1486 | 0.430 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2016 | 417 | 0.410 |
Why?
|
| Renal Insufficiency, Chronic | 4 | 2022 | 2208 | 0.380 |
Why?
|
| Kidney | 4 | 2020 | 7186 | 0.360 |
Why?
|
| Serum Sickness | 1 | 2007 | 28 | 0.300 |
Why?
|
| Kidney Function Tests | 3 | 2020 | 684 | 0.270 |
Why?
|
| Potassium | 2 | 2006 | 1336 | 0.200 |
Why?
|
| Micropore Filters | 1 | 2020 | 23 | 0.190 |
Why?
|
| Urate Oxidase | 1 | 2020 | 35 | 0.190 |
Why?
|
| Glycyrrhetinic Acid | 1 | 2020 | 18 | 0.190 |
Why?
|
| Glycyrrhiza | 1 | 2020 | 11 | 0.190 |
Why?
|
| Methemoglobinemia | 1 | 2020 | 44 | 0.190 |
Why?
|
| Mineralocorticoids | 1 | 2020 | 38 | 0.190 |
Why?
|
| Glycogen Storage Disease Type I | 1 | 2020 | 53 | 0.190 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2020 | 162 | 0.180 |
Why?
|
| Hematuria | 1 | 2020 | 235 | 0.160 |
Why?
|
| Urinalysis | 1 | 2020 | 369 | 0.160 |
Why?
|
| Glomerulonephritis | 1 | 2020 | 372 | 0.160 |
Why?
|
| Fibroblast Growth Factors | 2 | 2016 | 879 | 0.150 |
Why?
|
| Gene Expression Regulation | 3 | 2006 | 12072 | 0.150 |
Why?
|
| Hyperaldosteronism | 1 | 2020 | 240 | 0.150 |
Why?
|
| Fanconi Syndrome | 1 | 2017 | 35 | 0.150 |
Why?
|
| Liver Transplantation | 1 | 2007 | 2119 | 0.140 |
Why?
|
| Choristoma | 1 | 2017 | 213 | 0.130 |
Why?
|
| Cryoglobulinemia | 1 | 2015 | 87 | 0.130 |
Why?
|
| Sjogren's Syndrome | 1 | 2017 | 233 | 0.130 |
Why?
|
| Advance Care Planning | 1 | 2022 | 662 | 0.120 |
Why?
|
| Transcription, Genetic | 2 | 2005 | 7722 | 0.120 |
Why?
|
| Creatinine | 1 | 2020 | 1919 | 0.120 |
Why?
|
| Germinal Center | 1 | 2017 | 377 | 0.120 |
Why?
|
| Drug Monitoring | 1 | 2020 | 956 | 0.120 |
Why?
|
| Calciphylaxis | 1 | 2016 | 124 | 0.120 |
Why?
|
| Promoter Regions, Genetic | 1 | 2005 | 5867 | 0.120 |
Why?
|
| Renal Insufficiency | 1 | 2020 | 804 | 0.120 |
Why?
|
| Ambulatory Care Facilities | 1 | 2020 | 933 | 0.120 |
Why?
|
| Ribavirin | 1 | 2015 | 395 | 0.120 |
Why?
|
| Death, Sudden, Cardiac | 2 | 2020 | 1541 | 0.110 |
Why?
|
| Heparin | 1 | 2020 | 1637 | 0.110 |
Why?
|
| Myocardium | 1 | 2005 | 4776 | 0.100 |
Why?
|
| Interferon-alpha | 1 | 2015 | 895 | 0.100 |
Why?
|
| Kidney Failure, Chronic | 2 | 2016 | 2538 | 0.100 |
Why?
|
| Long QT Syndrome | 2 | 2005 | 453 | 0.100 |
Why?
|
| Diagnosis, Differential | 3 | 2020 | 12959 | 0.090 |
Why?
|
| Peritoneal Dialysis | 1 | 2011 | 146 | 0.090 |
Why?
|
| KATP Channels | 2 | 2007 | 45 | 0.090 |
Why?
|
| Terminal Care | 1 | 2022 | 1694 | 0.090 |
Why?
|
| Antibodies, Monoclonal | 1 | 2007 | 9274 | 0.090 |
Why?
|
| Potassium Channels, Inwardly Rectifying | 2 | 2007 | 150 | 0.090 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2015 | 783 | 0.080 |
Why?
|
| Patch-Clamp Techniques | 3 | 2007 | 964 | 0.080 |
Why?
|
| Disease Management | 2 | 2016 | 2459 | 0.080 |
Why?
|
| Potassium Deficiency | 1 | 2007 | 10 | 0.080 |
Why?
|
| Biopsy | 1 | 2020 | 6756 | 0.080 |
Why?
|
| Critical Illness | 1 | 2020 | 2670 | 0.080 |
Why?
|
| Genetic Testing | 1 | 2020 | 3444 | 0.070 |
Why?
|
| Hepatitis C, Chronic | 1 | 2015 | 1031 | 0.070 |
Why?
|
| Ultrasonography | 1 | 2020 | 5985 | 0.070 |
Why?
|
| Kidney Diseases | 1 | 2017 | 2149 | 0.070 |
Why?
|
| Ether-A-Go-Go Potassium Channels | 1 | 2005 | 70 | 0.070 |
Why?
|
| KCNQ1 Potassium Channel | 1 | 2005 | 104 | 0.070 |
Why?
|
| Methylprednisolone | 1 | 2007 | 387 | 0.070 |
Why?
|
| Antilymphocyte Serum | 1 | 2007 | 492 | 0.070 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2011 | 643 | 0.060 |
Why?
|
| Kidney Transplantation | 1 | 2020 | 4251 | 0.060 |
Why?
|
| Injections, Intravenous | 1 | 2007 | 1420 | 0.060 |
Why?
|
| Biophysics | 1 | 2006 | 383 | 0.060 |
Why?
|
| Fractures, Bone | 1 | 2016 | 1947 | 0.060 |
Why?
|
| Ion Transport | 1 | 2005 | 320 | 0.060 |
Why?
|
| Antiviral Agents | 1 | 2015 | 2987 | 0.060 |
Why?
|
| Potassium Channels | 1 | 2006 | 563 | 0.050 |
Why?
|
| Multiple Myeloma | 1 | 2020 | 5181 | 0.050 |
Why?
|
| Humans | 19 | 2022 | 744343 | 0.050 |
Why?
|
| Vitamin D | 1 | 2016 | 3223 | 0.050 |
Why?
|
| CHO Cells | 1 | 2005 | 1406 | 0.050 |
Why?
|
| Venous Thrombosis | 1 | 2011 | 1239 | 0.050 |
Why?
|
| Adult | 7 | 2020 | 214055 | 0.050 |
Why?
|
| Electrophysiology | 1 | 2005 | 1308 | 0.050 |
Why?
|
| Protein Subunits | 1 | 2005 | 959 | 0.050 |
Why?
|
| Cricetinae | 1 | 2005 | 2472 | 0.050 |
Why?
|
| In Situ Hybridization | 1 | 2005 | 1950 | 0.050 |
Why?
|
| Male | 14 | 2020 | 350118 | 0.050 |
Why?
|
| Organ Specificity | 1 | 2005 | 2008 | 0.050 |
Why?
|
| Rabbits | 1 | 2007 | 4894 | 0.050 |
Why?
|
| Hypertension | 1 | 2020 | 8480 | 0.040 |
Why?
|
| Middle Aged | 11 | 2020 | 213383 | 0.040 |
Why?
|
| Factor Xa | 1 | 2020 | 162 | 0.040 |
Why?
|
| Hypokalemia | 1 | 2020 | 153 | 0.040 |
Why?
|
| Adenosine Triphosphate | 1 | 2006 | 2025 | 0.040 |
Why?
|
| Blood Chemical Analysis | 1 | 2020 | 440 | 0.040 |
Why?
|
| Hypercalcemia | 1 | 2020 | 409 | 0.040 |
Why?
|
| Equipment Failure Analysis | 1 | 2020 | 868 | 0.040 |
Why?
|
| Ventricular Fibrillation | 1 | 2020 | 538 | 0.040 |
Why?
|
| Glucocorticoids | 1 | 2007 | 2107 | 0.040 |
Why?
|
| Cromakalim | 2 | 2007 | 19 | 0.040 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2006 | 3772 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2022 | 1677 | 0.040 |
Why?
|
| Diazoxide | 2 | 2007 | 57 | 0.040 |
Why?
|
| Medical Records, Problem-Oriented | 1 | 2016 | 35 | 0.040 |
Why?
|
| Fatal Outcome | 1 | 2020 | 1850 | 0.030 |
Why?
|
| Aldosterone | 1 | 2020 | 877 | 0.030 |
Why?
|
| Muscle, Skeletal | 2 | 2007 | 4931 | 0.030 |
Why?
|
| Blood Coagulation | 1 | 2020 | 1127 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 2020 | 1462 | 0.030 |
Why?
|
| Acute Kidney Injury | 1 | 2007 | 1972 | 0.030 |
Why?
|
| Observer Variation | 1 | 2020 | 2593 | 0.030 |
Why?
|
| Radiography, Thoracic | 1 | 2020 | 1265 | 0.030 |
Why?
|
| Aged | 6 | 2022 | 163280 | 0.030 |
Why?
|
| Cardiomyopathies | 1 | 2005 | 1912 | 0.030 |
Why?
|
| Rats, Wistar | 2 | 2007 | 1901 | 0.030 |
Why?
|
| Renal Dialysis | 1 | 2022 | 1786 | 0.030 |
Why?
|
| Hydrocortisone | 1 | 2020 | 1826 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2020 | 10943 | 0.030 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2020 | 980 | 0.030 |
Why?
|
| Female | 9 | 2020 | 380194 | 0.020 |
Why?
|
| Genetic Variation | 1 | 2005 | 6544 | 0.020 |
Why?
|
| Reproducibility of Results | 2 | 2020 | 19905 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2005 | 13033 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2005 | 15519 | 0.020 |
Why?
|
| Oxygen | 1 | 2020 | 4189 | 0.020 |
Why?
|
| Predictive Value of Tests | 2 | 2016 | 15076 | 0.020 |
Why?
|
| Hypokalemic Periodic Paralysis | 1 | 2007 | 4 | 0.020 |
Why?
|
| Phosphates | 1 | 2011 | 786 | 0.020 |
Why?
|
| Sarcolemma | 1 | 2007 | 66 | 0.020 |
Why?
|
| Animals | 4 | 2007 | 168757 | 0.020 |
Why?
|
| Potassium Channel Blockers | 1 | 2007 | 171 | 0.020 |
Why?
|
| Tolbutamide | 1 | 2006 | 23 | 0.020 |
Why?
|
| Receptors, Drug | 1 | 2006 | 160 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2005 | 12208 | 0.020 |
Why?
|
| Glyburide | 1 | 2006 | 113 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2022 | 9959 | 0.020 |
Why?
|
| Anticoagulants | 1 | 2020 | 4599 | 0.020 |
Why?
|
| Electroencephalography | 1 | 2020 | 6150 | 0.020 |
Why?
|
| Founder Effect | 1 | 2005 | 189 | 0.020 |
Why?
|
| Parathyroid Hormone | 1 | 2011 | 1801 | 0.020 |
Why?
|
| Treatment Outcome | 2 | 2011 | 63114 | 0.020 |
Why?
|
| Patient Selection | 1 | 2016 | 4215 | 0.020 |
Why?
|
| Membrane Potentials | 1 | 2007 | 1137 | 0.010 |
Why?
|
| Mutation | 2 | 2005 | 29786 | 0.010 |
Why?
|
| Phenotype | 3 | 2006 | 16365 | 0.010 |
Why?
|
| Cost-Benefit Analysis | 1 | 2016 | 5391 | 0.010 |
Why?
|
| Vasodilator Agents | 1 | 2007 | 977 | 0.010 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2006 | 560 | 0.010 |
Why?
|
| Muscle Fibers, Skeletal | 1 | 2006 | 555 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2011 | 4217 | 0.010 |
Why?
|
| Lung | 1 | 2020 | 9856 | 0.010 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2006 | 789 | 0.010 |
Why?
|
| DNA Primers | 1 | 2006 | 2892 | 0.010 |
Why?
|
| Linear Models | 1 | 2011 | 5952 | 0.010 |
Why?
|
| Muscles | 1 | 2006 | 1614 | 0.010 |
Why?
|
| Quality of Life | 1 | 2022 | 12804 | 0.010 |
Why?
|
| Rats | 2 | 2007 | 24260 | 0.010 |
Why?
|
| Disease Progression | 1 | 2016 | 13284 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2006 | 4751 | 0.010 |
Why?
|
| Kinetics | 1 | 2006 | 6473 | 0.010 |
Why?
|
| Retrospective Studies | 2 | 2016 | 77449 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2020 | 20129 | 0.010 |
Why?
|
| United States | 2 | 2016 | 69872 | 0.010 |
Why?
|
| Antihypertensive Agents | 1 | 2006 | 2046 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2020 | 53288 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2020 | 35421 | 0.010 |
Why?
|
| Hypoglycemic Agents | 1 | 2006 | 2872 | 0.010 |
Why?
|
| Electrocardiography | 1 | 2005 | 6442 | 0.010 |
Why?
|
| Models, Statistical | 1 | 2006 | 5102 | 0.010 |
Why?
|
| Time Factors | 1 | 2011 | 40075 | 0.010 |
Why?
|
| Child | 1 | 2017 | 77709 | 0.010 |
Why?
|
| Adolescent | 1 | 2017 | 85781 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2005 | 40561 | 0.000 |
Why?
|